Topical mecamylamine formulations for ocular administration and uses thereof

A method for treating or preventing conditions mediated by neovascularization, abnormal angiogenesis, vascular permeability, or combinations thereof, of posterior tissues of the eye comprising the step of

• a) topically applying to one or both eyes of an individual in need thereof a formulation comprising mecamylamine, or a pharmaceutically acceptable salt thereof, and a carrier suitable for topical administration to the eye,
• wherein the mecamylamine or a pharmaceutically acceptable salt thereof is present in the formulation in an amount sufficient to deliver a therapeutically effective amount of mecamylamine to one or more of the posterior tissues of the eye for the treatment or prevention of conditions mediated by neovascularization, abnormal angiogenesis, vascular permeability, or combinations thereof, of posterior tissues of the eye.

The method of claim 1112, wherein the one or more tonicity agent(s) is a polyol.

The method of claim 1113, wherein the polyol is a sugar alcohol, trihydroxy alcohol, propylene glycol or polyethylene glycol.

A method for treating or preventing conditions mediated by neovascularization, abnormal angiogenesis, vascular permeability, or combinations thereof, of anterior tissues of the eye comprising the step of

• a) topically applying to one or both eyes of an individual in need thereof a formulation comprising mecamylamine, or a pharmaceutically acceptable salt thereof, and a carrier suitable for topical administration to the eye,
• wherein the mecamylamine or a pharmaceutically acceptable salt thereof is present in the formulation in an amount sufficient to deliver a therapeutically effective amount of mecamylamine to one or more of the anterior tissues or fluids of the eye for the treatment or prevention of conditions mediated by neovascularization, abnormal angiogenesis, vascular permeability, or combinations thereof, of anterior tissues of the eye.

A pharmaceutical formulation comprising mecamylamine, or a pharmaceutically acceptable salt thereof, water and a gel-forming polymer formulated for ocular topical administration,

• wherein the gel-forming polymer is selected such that when the formulation is topically administered to a rabbit eye, the ratio of the concentration of mecamylamine present in the choroidal and retinal tissue, measured in units of ng/g, to the concentration of mecamylamine in plasma measured in units of ng/mL ([ng/g mecamylamine choroidal+retinal tissue]:
• [ng/mL plasma]) is at least about 300:1.